Kamada ( (IL:KMDA) ) has shared an update.
On March 5, 2025, Kamada Ltd. announced a special cash dividend of $0.20 per share, totaling approximately $11.5 million, payable on April 7, 2025. This decision follows a record financial performance in 2024, highlighting the company’s strong market position and commitment to shareholder value. Kamada’s strategic focus on growth through commercial activities, business development, and plasma collection expansion positions it for continued success. The dividend declaration underscores confidence in Kamada’s business prospects and its dedication to enhancing shareholder value.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions. The company focuses on organic commercial growth, business development, plasma collection expansion, and advancing product candidates like Inhaled AAT. Kamada operates plasma collection centers in the U.S. and is supported by FIMI Opportunity Funds, its controlling shareholder.
YTD Price Performance: 4.42%
Average Trading Volume: 198,073
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $376.8M
For an in-depth examination of KMDA stock, go to TipRanks’ Stock Analysis page.